## SENATE BILL NO. 378–SENATOR CANCELA

## MARCH 20, 2019

Referred to Committee on Health and Human Services

SUMMARY—Revises provisions relating to the pricing of prescription drugs. (BDR 40-574)

FISCAL NOTE: Effect on Local Government: No. Effect on the State: Yes.

EXPLANATION - Matter in *bolded italics* is new; matter between brackets [omitted material] is material to be omitted.

AN ACT relating to prescription drugs; establishing the Prescription Drug Affordability Board and the Prescription Drug Affordability Stakeholder Council; imposing certain requirements to prevent conflicts of interest involving a member of the Board; authorizing the Board to employ certain persons; requiring the Board to impose an assessment on manufacturers of prescription drugs; authorizing the Board to review the prices of certain prescription drugs; providing for the confidentiality of certain information used in such a review; authorizing the Board to prescribe an upper payment limit for a prescription drug that meets certain requirements after such a review; authorizing written appeals to the Board; requiring the Board to submit an annual report to the Legislature; revising provisions concerning coverage of prescription drugs under Medicaid and the Children's Health Insurance Program; and providing other matters properly relating thereto.

## Legislative Counsel's Digest:

Existing law requires a manufacturer of prescription drugs to report certain information relating to the prices of drugs determined by the Department of Health and Human Services to be essential for treating diabetes in this State. (NRS 439B.635-439B.645) Existing law requires the Department to annually analyze that information and compile a report concerning the price of those drugs. (NRS 439B.650) Section 12 of this bill establishes the Prescription Drug Affordability Board and provides for the appointment of regular and alternate members of the Board. Section 12: (1) requires each such member to have expertise in the





9 economics of health care or the practice of clinical medicine; and (2) prohibits a 10 member of the board from holding certain positions with a manufacturer or a trade 11 association of manufacturers. Section 13 of this bill prescribes requirements 12 13 governing the procedure of the Board. Section 13 additionally requires a member of the Board to recuse himself or herself from certain decisions and prohibits a 14 member of the Board from accepting certain financial benefits, gifts or donations. 15 Sections 12 and 13 require the disclosure and publication of certain information 16 concerning a conflict of interest involving a member of the Board. Section 14 of 17 this bill provides for the appointment of an Executive Director, a General Counsel 18 and other employees of the Board. Section 13 prohibits an employee of the Board 19 from accepting certain gifts and donations. Section 15 of this bill establishes the 20 Prescription Drug Affordability Stakeholder Council and prescribes the qualifications of the members of the Council.

qualifications of the members of the Council.
Section 16 of this bill establishes the Prescription Drug Affordability Account to pay for the expenses of the Board and the Council. Section 17 of this bill requires the Board to impose an assessment on manufacturers and requires the Board to deposit such assessments in the Account.
Section 18 of this bill requires the Board to identify prescription drugs that meet certain criteria indicating that the price of the prescription drug may be creating significant challenges for insurers and patients in this State. Section 18

Section 18 of this bill requires the Board to identify prescription drugs that meet certain criteria indicating that the price of the prescription drug may be creating significant challenges for insurers and patients in this State. Section 18 29 requires the Board, in consultation with the Council, to determine whether to  $\overline{30}$ conduct a review to determine whether the price of a prescription drug identified by 31 the Board as meeting those criteria is creating significant challenges for insurers 32 33 and patients in this State. Section 19 of this bill prescribes the criteria the Board must consider when conducting such a review. Section 20 of this bill authorizes the 34 Board to: (1) use certain information concerning the price of a prescription drug 35 when conducting such a review; and (2) take certain measures to acquire such 36 information. Sections 13, 20, 27 and 28 of this bill provide for the confidentiality 37 of proprietary information considered by the Board. Section 24 of this bill requires 38 the Department to provide to the Board any information concerning the price of 39 essential diabetes drugs and certain other information upon request.

40 Section 21 of this bill requires the Board to prescribe a recommended upper 41 payment limit for all purchases of a prescription drug for which the Board 42 determines that the price of the drug is creating significant challenges for insurers 43 and patients in this State. Section 26 of this bill exempts such upper payment limits 44 from the requirements applicable to regulations of state agencies generally. 45 Sections 29, 30 and 32-36 of this bill make any upper payment limits prescribed by 46 the Board after January 1, 2024, mandatory. Section 39 of this bill requires the 47 Board to conduct an additional review of the price of a prescription drug for which 48 a recommended upper payment limit was prescribed on or before December 31, 49 2023, and, if appropriate, to prescribe a mandatory upper payment limit for that 50 drug.

51 Section 22 of this bill authorizes a person aggrieved by a decision of the Board 52 to submit a written appeal to the Board. Section 23 of this bill: (1) authorizes the 53 Board to adopt regulations and enter into contracts; and (2) requires the Board to 54 submit to the Legislature an annual report concerning trends in prescription drug 55 pricing and the reviews conducted by the Board.

**Section 31** of this bill requires any contract between the Department of Health and Human Services and a pharmacy benefit manager to provide services related to prescription drug coverage under Medicaid or the Children's Health Insurance Program to require the pharmacy benefit manager to provide to the Department any information concerning such services provided pursuant to the contract. If the Department does not enter into such a contract, **section 31** also requires the Department to directly manage and coordinate such services.





63 Existing law requires the Department to develop a list of preferred prescription 64 drugs to be used for the Medicaid program. (NRS 422.4025) Section 34 of this bill requires the list to be used as the formulary for any prescription drug coverage provided pursuant to Medicaid or the Children's Health Insurance Program through 65 66 managed care. 67

> THE PEOPLE OF THE STATE OF NEVADA. REPRESENTED IN SENATE AND ASSEMBLY. DO ENACT AS FOLLOWS:

**Section 1.** Chapter 439B of NRS is hereby amended by adding 1 2 thereto the provisions set forth as sections 2 to 23, inclusive, of this 3 act.

Sec. 2. As used in sections 2 to 23, inclusive, of this act, 4 5 unless the context otherwise requires, the words and terms defined in sections 3 to 11, inclusive, of this act have the meanings 6 7 ascribed to them in those sections.

8 Sec. 3. "Board" means the Prescription Drug Affordability 9 Board established by section 12 of this act.

10 Sec. 4. "Brand name prescription drug" means a prescription drug that is produced or distributed in accordance 11 with an original new drug application approved pursuant to 21 12 U.S.C. § 355(c). The term does not include an authorized generic 13 drug, as defined in 42 C.F.R. § 447.502. 14

Sec. 5. "Council" means the Prescription Drug Affordability 15 Stakeholder Council established by section 15 of this act. 16 17

Sec. 6. "Generic prescription drug" means:

1. A prescription drug that is marketed or distributed in 18 accordance with an abbreviated new drug application that has 19 been approved pursuant to 21 U.S.C. § 355(j); 20

2. An authorized generic drug, as defined in 42 C.F.R. § 21 22 447.502; and

23 3. A prescription drug that entered the market before January 24 1, 1962, and was not originally marketed under a new drug 25 application.

"Health carrier" means an entity subject to the 26 Sec. 7. 27 insurance laws and regulations of this State, or subject to the jurisdiction of the Commissioner of Insurance, that contracts or 28 offers to contract to provide, deliver, arrange for, pay for or 29 reimburse any of the costs of health care services, including, 30 without limitation, a sickness and accident health insurance 31 32 company, a health maintenance organization, a nonprofit hospital 33 and health service corporation or any other entity providing a plan 34 of health insurance, health benefits or health care services.

"Manufacturer" has the meaning ascribed to it in 35 Sec. 8. NRS 639.009. 36





1 Sec. 9. "Pharmacy benefit manager" has the meaning 2 ascribed to it in NRS 683A.174.

3 Sec. 10. "Upper payment limit" means the maximum amount 4 that the Board recommends that a health carrier or other person 5 pay for a dose of a prescription drug pursuant to section 21 of this 6 act.

7 Sec. 11. "Wholesale acquisition cost" has the meaning 8 ascribed to it in NRS 439B.620

9 Sec. 12. 1. The Prescription Drug Affordability Board is 10 hereby established. The Board consists of the following regular 11 members:

(a) One member appointed by the Governor;

13 (b) One member appointed by the Majority Leader of the 14 Senate;

15 (c) One member appointed by the Speaker of the Assembly;

16 (d) One member appointed by the Attorney General; and

17 (e) One member jointly appointed by the Majority Leader of 18 the Senate and the Speaker of the Assembly. The member 19 appointed pursuant to this paragraph shall serve as the Chair of 20 the Board.

21 **2.** In addition to the regular members appointed to the Board 22 pursuant to subsection 1:

(a) The Governor shall appoint one alternate member;

24 (b) The Majority Leader of the Senate shall appoint one 25 alternate member; and

(c) The Speaker of the Assembly shall appoint one alternate
 member.

28 3. A regular member of the Board appointed pursuant to 29 subsection 1 or an alternate member of the Board appointed 30 pursuant to subsection 2:

31 (a) Must have expertise in the economics of health care or the 32 practice of clinical medicine; and

(b) Must not be an employee, officer, member of the executive
board or consultant of a manufacturer or a trade association for
manufacturers.

Before being appointed as a regular or alternate member 36 4. 37 of the Board, a person shall disclose to the authority considering the appointment any potential conflict of interest, including, 38 without limitation, a financial interest or personal association, 39 that may create bias or the appearance of bias in matters related to 40 the duties of the Board. An appointing authority shall disclose to 41 42 the Chair of the Board any conflict of interest reported to him or 43 her not later than 5 days after the identification of the conflict of interest. The Board shall post on an Internet website maintained 44 45 by the Board notification of the conflict of interest, including,



12



1 without limitation, the type and significance of the conflict of 2 interest and the name of the potential member involved.

5. In appointing the regular and alternate members of the Board described in subsections 1 and 2, the appointing authorities shall coordinate the appointments when practicable so that the regular and alternate members of the Board reflect the ethnic and geographic diversity of this State.

8 After the initial terms, each regular and alternate member 6. of the Board serves for a term of 4 years. Each member of the 9 Board continues in office until his or her successor is appointed. 10 11 Members may be reappointed for additional terms of 4 years in the 12 same manner as the original appointments. Any vacancy 13 occurring in the membership of the Board must be filled in the same manner as the original appointment not later than 30 days 14 15 after the vacancy occurs.

16 7. Each regular or alternate member of the Board who is not 17 an officer or employee of this State or a political subdivision of 18 this State is entitled to receive a salary of \$80 per day while 19 engaged in the business of the Board.

8. While engaged in the business of the Board, each regular and alternate member of the Board is entitled to receive the per diem allowance and travel expenses provided for state officers and employees generally.

9. A majority of the members of the Board constitutes a
quorum for the transaction of business, and a majority of a
quorum present at any meeting is sufficient for any official action
taken by the Board.

28 10. A regular or alternate member of the Board who is an 29 officer or employee of this State or a political subdivision of this State must be relieved from his or her duties without loss of 30 regular compensation to prepare for and attend meetings of the 31 Board and perform any work necessary to carry out the duties of 32 33 the Board in the most timely manner practicable. A state agency or 34 political subdivision of this State shall not require an officer or 35 *employee who is a member of the Board to:* 

(a) Make up the time he or she is absent from work to carry
out his or her duties as a member of the Board; or

(b) Take annual leave or compensatory time for the absence.

**Sec. 13.** 1. Except as otherwise provided in this subsection, the Board shall meet at the call of the Chair of the Board or a majority of its regular members and not less than once every 6 weeks. The Board may cancel or postpone a meeting if there are no prescription drugs to review pursuant to section 19 of this act.

44 2. The Board may close any portion of a meeting during 45 which it considers proprietary information concerning a



prescription drug. Any portion of a meeting that is closed pursuant
 to this subsection is not subject to the provisions of chapter 241 of
 NRS. The Board shall not vote on any matter during the closed

4 *portion of a meeting.* 

5 3. If any regular member of the Board informs the Chair that 6 the member will be unable to attend a scheduled meeting of the 7 Board, the Chair must select an alternate member to replace the 8 regular member at that meeting only, with all the duties, rights 9 and privileges of the replaced member.

4. A regular or alternate member of the Board shall recuse
himself or herself from a decision of the Board if the member or a
member of his or her immediate family may receive a direct
financial benefit, including, without limitation, honoraria, fees,
stock or an increase in the value of an investment, deriving from
the decision or any action taken pursuant to the decision.

16 5. A regular or alternate member of the Board shall not 17 accept from a manufacturer or other person or entity who 18 manufactures or distributes products or services related to 19 prescription drugs or a person who owns or invests in a 20 manufacturer or other such person or entity financial benefits 21 that, in aggregate, exceed \$5,000 in any calendar year.

6. A regular or alternate member, independent contractor or employee of the Board shall not accept any gift or donation of services or property that creates a potential conflict of interest or has the appearance of creating bias concerning the work of the Board.

27 7. A regular or alternate member of the Board shall disclose 28 to the Chair of the Board any conflict of interest that affects the 29 member before the meeting of the Board immediately following the identification of the conflict of interest or not later than 5 days 30 after the identification of the conflict of interest, whichever is 31 32 earlier. The Chair may recuse a member who discloses a conflict of interest from any decision of the Board to which the conflict of 33 interest is relevant. If a member who discloses a conflict of interest 34 is not recused, the Board must post on an Internet website 35 maintained by the Board notification of the conflict of interest, 36 including, without limitation, a description of the type and 37 significance of the conflict of interest and the name of the member 38 39 involved.

40 Sec. 14. 1. Upon approval by a majority of the members of 41 the Board, the Board shall appoint an Executive Director, General 42 Counsel and such other employees as the Board deems necessary.

43 2. The Executive Director and General Counsel are in the 44 unclassified service of the State and serve at the pleasure of the





Board. Any other employees of the Board are in the classified 1 2 service of the State. 3 3. The Board shall establish the qualifications, powers and 4 duties of the Executive Director and General Counsel. 5 Sec. 15. *1. The* **Prescription** Drug *Affordability* Stakeholder Council is hereby established. 6 7 The Speaker of the Assembly shall appoint to the Council: 2. 8 (a) One member who is a representative of a statewide 9 organization that advocates for consumers of health care; 10 (b) One member who is a representative of a statewide 11 organization that advocates for senior citizens; 12 (c) One member who is a representative of a statewide organization that advocates for members of minority groups; 13 (d) One member who is a representative of an employee 14 15 organization; (e) Two members who perform scientific research concerning 16 17 prescription drugs; and 18 (f) One member who is a representative of the general public. 19 3. The Majority Leader of the Senate shall appoint to the 20 Council: 21 (a) One member who is a representative of physicians; 22 (b) One member who is a representative of nurses: 23 (c) One member who is a representative of hospitals; 24 (d) One member who is a representative of health insurers; (e) One member who is a representative of the Budget Division 25 26 of the Office of Finance; (f) One member who performs clinical research concerning 27 28 prescription drugs; and 29 (g) One member who is a representative of the general public. 30 4. The Governor shall appoint to the Council: (a) One member who is a representative of manufacturers of 31 32 brand name prescription drugs; (b) One member who is a representative of manufacturers of 33 34 generic prescription drugs: (c) One member who is a representative of employers; 35 36 (d) One member who is a representative of pharmacy benefit 37 managers; 38 (e) One member who is a representative of pharmacists; 39 (f) One pharmacologist; and (g) One member who is a representative of the general public. 40 In appointing the members of the Council described in 41 5. 42 subsections 2, 3 and 4, the appointing authorities shall coordinate 43 the appointments when practicable so that the members of the Council reflect the ethnic and geographic diversity of this State. 44





– 7 –

Each member of the Council must have knowledge in at 1 6. 2 least one of the following subject areas: 3

(a) The business models of manufacturers.

6

7

8

(b) The supply chain for the production and distribution of 4 5 prescription drugs.

(c) The practice of medicine or clinical training.

(d) Perspectives of consumers of prescription drugs.

(e) Trends in and drivers of the cost of health care.

9 (f) Clinical research or other research concerning the provision of health care. 10

11 (g) The Silver State Health Insurance Exchange established by 12 NRS 6951.200.

13 7. After the initial terms, each member of the Council serves 14 for a term of 3 years. Each member of the Council continues in 15 office until his or her successor is appointed. Members may be 16 reappointed for additional terms of 3 years in the same manner as the original appointments. Any vacancy occurring in the 17 membership of the Council must be filled in the same manner as 18 the original appointment not later than 30 days after the vacancy 19 20 occurs.

21 The members of the Council serve without compensation **8**. 22 but are entitled to receive the per diem allowance and travel 23 expenses provided for state officers and employees generally.

24 At its first meeting and annually thereafter, the Council 9. shall elect a Chair from among its members. A majority of the 25 26 members of the Council constitutes a quorum for the transaction 27 of business, and a majority of a quorum present at any meeting is 28 sufficient for any official action taken by the Council.

29 10. A member of the Council who is an officer or employee of 30 this State or a political subdivision of this State must be relieved from his or her duties without loss of regular compensation to 31 32 prepare for and attend meetings of the Council and perform any work necessary to carry out the duties of the Council in the most 33 timely manner practicable. A state agency or political subdivision 34 of this State shall not require an officer or employee who is a 35 36 *member of the Council to:* 

37 (a) Make up the time he or she is absent from work to carry 38 out his or her duties as a member of the Council; or

(b) Take annual leave or compensatory time for the absence.

Sec. 16. 1. The Prescription Drug Affordability Account is 40 hereby created in the State General Fund. The Account must be 41 42 administered by the Board. 43

The interest and income earned on: 2.

44 (a) The money in the Account, after deducting any applicable 45 charges; and





1 (b) Unexpended appropriations made to the Account from the 2 State General Fund,

3 → must be credited to the Account.

Any money remaining in the Account at the end of a fiscal
year including, without limitation, any unexpended appropriations
made to the Account from the State General Fund, does not revert
to the State General Fund, and the balance in the Account must
be carried forward to the next fiscal year.

9 4. The Board may accept gifts and grants of money from any 10 source for deposit in the Account.

11 5. The money in the Account may only be used to pay the 12 expenses incurred by the Board and the Council to perform the 13 duties prescribed in sections 2 to 23, inclusive, of this act.

14

26

Sec. 17. The Board shall:

15 1. Impose on each manufacturer that sells prescription drugs 16 for distribution in this State an annual assessment equal to the 17 percentage of the total sales of prescription drugs in this State that 18 are attributable to the manufacturer multiplied by the total 19 estimated costs of the Board and Council to perform the duties 20 prescribed by sections 2 to 23, inclusive, of this act during the 21 immediately preceding fiscal year.

22 2. Deposit the assessments collected pursuant to subsection 1
23 in the Prescription Drug Affordability Account created by section
24 16 of this act.

25 Sec. 18. 1. The Board shall identify:

(a) Each brand name prescription drug for which:

27 (1) If the prescription drug is a new drug, the wholesale 28 acquisition cost is \$30,000 or more per year or for a course of 29 treatment; or

30 (2) The wholesale acquisition cost has increased by \$3,000 31 or more in any 12-month period or, if a course of treatment using 32 the prescription drug is less than 12 months, during the time 33 period of a course of treatment.

34 (b) Each new biosimilar prescription drug that has a wholesale 35 acquisition cost that is not at least 15 percent lower than the brand 36 name prescription drug to which the new prescription drug is 37 biosimilar;

(c) Each generic prescription drug for which the wholesale
 acquisition cost:

40 (1) Is \$100 or more for:

41 (I) A supply of the drug for 30 days or less, as calculated 42 using the recommended dosage approved by the United States 43 Food and Drug Administration; or

44 (II) If no such recommended dosage has been approved, 45 for one unit of the drug; or





1 (2) Increased by 200 percent or more during the 2 immediately preceding calendar year; and

3 (d) Any other prescription drug for which the Board 4 determines, in consultation with the Council, that the price of the 5 drug may be creating significant challenges for insurers and 6 patients in this State.

7 2. For each prescription drug identified pursuant to 8 subsection 1, the Board shall, in consultation with the Council, 9 determine whether to conduct a review of price of the drug 10 pursuant to section 19 of this act. When determining whether to 11 conduct such a review, the Board shall consider, without 12 limitation, the average copayment or coinsurance required for the 13 prescription drug in this State.

14 3. The dollar amounts set forth in this section must be 15 adjusted by the Board every year by an amount equal to the 16 percentage increase in the Consumer Price Index, Medical, for the 17 immediately preceding year.

18 4. As used in this section, "biosimilar" means a prescription 19 drug that is produced or distributed in accordance with a biologics 20 license application approved pursuant to 42 U.S.C. § 262(k)(3).

21 Sec. 19. 1. The Board may review the price of any 22 prescription drug identified as meeting the criteria prescribed by 23 section 18 of this act to determine whether the price of the 24 prescription drug is creating significant challenges for insurers 25 and patients in this State.

26 2. In making a determination pursuant to subsection 1, the 27 Board shall consider, to the extent that such information is 28 available:

29 (a) The wholesale acquisition cost of the prescription drug;

30 (b) The average discount or rebate that the manufacturer of 31 the prescription drug provides to health carriers in connection 32 with the sale of the prescription drug in this State and the 33 percentage of the wholesale acquisition cost of the prescription 34 drug that is covered by that average discount or rebate;

(c) The average discount or rebate that the manufacturer of
the prescription drug provides to pharmacy benefit managers in
connection with the sale of the prescription drug in this State and
the percentage of the wholesale acquisition cost of the prescription
drug that is covered by that average discount or rebate;

40 (d) The prices at which comparable alternative prescription 41 drugs are sold in this State;

42 (e) The average discount or rebate that the manufacturers of 43 comparable alternative prescription drugs provide to health 44 carriers and pharmacy benefit managers in connection with the 45 sale of those alternative prescription drugs in this State;





alternative prescription drugs on such services; the prescription drug in this State; and (k) Any other factors prescribed by regulation of the Board. 14 3. 2, the Board may consider: this State: for marketing prescription drugs directly to consumers that is: taxes; and 27 (2) Attributable to the prescription drug; recent tax year; manufacturer; and (e) Any other factor prescribed by regulation of the Board. 32 Sec. 20. 1. In conducting a review pursuant to this section manufacturer. 2. The Board may enter into a S B 3 7 8

(f) The cost to health carriers to provide covered persons with 1 2 access to the prescription drug in this State;

3 (g) The impact of the price of the prescription drug on access 4 to the prescription drug in this State;

(h) The current or expected monetary value in this State of 5 patient access programs that are specific to the prescription drug 6 7 and supported by the manufacturer of the prescription drug;

8 (i) The impact of the price of the prescription drug on the cost of public health services, medical services and social services in 9 this State relative to the impact of the prices of comparable 10 11

12 (j) The average copayment or coinsurance paid by patients for 13

15 If the Board is unable to make a determination pursuant to subsection 1 after considering the factors prescribed by subsection 16 17

18 (a) The research and development costs of the manufacturer, as indicated in publicly available tax documents or information 19 20 filed with the Securities and Exchange Commission for the most 21 recent tax year, in proportion to the sales of the manufacturer in 22

23 (b) The percentage of the amount spent by the manufacturer 24

25 (1) Eligible for favorable treatment with respect to federal 26

28 (c) Gross and net revenues of the manufacturer for the most 29

30 (d) Any additional relevant factor recommended by the 31

33 19 of this act, the Board may use any information relating to the 34 selection of the price of the prescription drug by the manufacturer, 35 including, without limitation, publicly available information, 36 37 information disclosed to the Department pursuant to NRS 439B.600 to 439B.695, inclusive, information obtained through a 38 memorandum of understanding entered into pursuant to 39 subsection 2 and information requested and obtained from the 40 41

42 *memorandum* of 43 understanding with any agency of another State for the sharing of 44 information concerning the prices of prescription drugs,

1 including, without limitation, information reported to the 2 Department pursuant to NRS 439B.600 to 439B.695, inclusive.

3 3. Except as otherwise provided in this subsection, any proprietary information disclosed to the Board pursuant to this 4 5 section is confidential and is not a public record. Such information may be disclosed to an agency of another state 6 pursuant to a memorandum of understanding entered into under 7 8 the provisions of subsection 2 if the agency has requirements concerning the confidentiality of such information similar to those 9 prescribed by this subsection. 10

11 4. Failure of a manufacturer to provide information 12 requested by the Board pursuant to subsection 1 does not affect 13 the authority of the Board to conduct a review pursuant to section 14 19 of this act or to prescribe an upper payment limit pursuant to 15 section 21 of this act.

Sec. 21. 1. If, after conducting a review pursuant to section 16 19 of this act, the Board determines that the price of a prescription 17 18 drug is creating significant challenges for insurers and patients in this State, the Board shall prescribe a recommended upper 19 20 payment limit for purchases of the prescription drug in this State. When establishing a recommended upper payment limit for a 21 22 prescription drug, the Board shall consider, to the extent that such 23 information is available and relevant:

24 25

28

(a) The cost of administering the prescription drug;

(b) The cost of delivering the prescription drug to consumers;

26 (c) Any other relevant administrative costs related to the 27 prescription drug; and

(d) The information described in section 19 of this act.

29 2. The Board may revise or rescind a recommended upper 30 payment limit imposed pursuant to this section if, after conducting 31 a review pursuant to section 19 of this act, it determines that 32 conditions warrant the revision or rescinding of the upper 33 payment limit, as applicable.

34 3. The Board shall collaborate with the Council, 35 manufacturers, health carriers, consumers of prescription drugs 36 and other interested persons to:

(a) Establish and refine a methodology to for prescribing
upper payment limits pursuant to this section; and

39 (b) Improve the quality and quantity of information received 40 by the Board pursuant to section 20 of this act.

41 Sec. 22. 1. Any person aggrieved by a decision of the Board 42 may submit a written appeal to the Board not later than 30 days 43 after the date of the decision. The Board shall rule on the appeal

44 not later than 60 days after receiving the appeal.





1 2. A decision of the Board concerning an appeal pursuant to 2 subsection 1 is a final decision for purposes of judicial review. 3 Sec. 23. 1. The Board may: (a) Adopt any regulations necessary to carry out the provisions 4 5 of sections 2 to 23, inclusive, of this act. 6 (b) Enter into any contract necessary to carry out the 7 provisions of sections 2 to 23, inclusive, of this act. 8 2. On or before December 31 of each year, the Board shall submit to the Director of the Legislative Counsel Bureau for 9 transmittal to the Legislature a report that includes, without 10 11 *limitation*: 12 (a) Information concerning trends in the price of prescription 13 drugs: 14 (b) The number of prescription drugs that were reviewed pursuant to section 19 of this act and the outcomes of such 15 reviews, any appeals submitted pursuant to section 22 of this act 16 17 and any judicial review of such appeals; and (c) Any recommendations of the Board to increase the 18 19 affordability of prescription drugs in this State. 20 **Sec. 24.** NRS 439B.670 is hereby amended to read as follows: 21 439B.670 1. Except as otherwise provided in subsection 2 22 and subsection 3 of NRS 439B.660, the Department shall: 23 (a) Place or cause to be placed on the Internet website 24 maintained by the Department: 25 (1) The information provided by each pharmacy pursuant to 26 NRS 439B.655: 27 (2) The information compiled by a nonprofit organization 28 pursuant to NRS 439B.665 if such a report is submitted pursuant to 29 paragraph (b) of subsection 1 of that section; 30 (3) The lists of prescription drugs compiled by the 31 Department pursuant to NRS 439B.630; 32 (4) The wholesale acquisition cost of each prescription drug 33 reported pursuant to NRS 439B.635; and (5) The reports compiled by the Department pursuant to NRS 34 439B.650 and 439B.660. 35 36 (b) Ensure that the information placed on the Internet website 37 maintained by the Department pursuant to paragraph (a) is 38 organized so that each individual pharmacy, manufacturer and 39 nonprofit organization has its own separate entry on that website; 40 and 41 (c) Ensure that the usual and customary price that each 42 pharmacy charges for each prescription drug that is on the list 43 prepared pursuant to NRS 439B.625 and that is stocked by the 44 pharmacy:





1 (1) Is presented on the Internet website maintained by the 2 Department in a manner which complies with the requirements of 3 NRS 439B.675; and

4 (2) Is updated not less frequently than once each calendar 5 quarter.

Nothing in this subsection prohibits the Department from
determining the usual and customary price that a pharmacy charges
for a prescription drug by extracting or otherwise obtaining such
information from claims reported by pharmacies to the Medicaid
program.

11 2. If a pharmacy is part of a larger company or corporation or a 12 chain of pharmacies or retail stores, the Department may present the 13 pricing information pertaining to such a pharmacy in such a manner 14 that the pricing information is combined with the pricing 15 information relative to other pharmacies that are part of the same 16 company, corporation or chain, to the extent that the pricing 17 information does not differ among those pharmacies.

18 3. The Department may establish additional or alternative 19 procedures by which a consumer who is unable to access the 20 Internet or is otherwise unable to receive the information described 21 in subsection 1 in the manner in which it is presented by the 22 Department may obtain that information:

23

(a) In the form of paper records;

24

(b) Through the use of a telephonic system; or

(c) Using other methods or technologies designed specifically to
 assist consumers who are hearing impaired or visually impaired.

4. The Department shall provide to the Prescription Drug Affordability Board established pursuant to section 12 of this act any information submitted to the Department pursuant to NRS 439B.600 to 439B.695, inclusive, upon the request of the Board.

5. As used in this section, "usual and customary price" means
the usual and customary charges that a pharmacy charges to the
general public for a drug, as described in 42 C.F.R. § 447.512.
Sec. 25. NRS 232.320 is hereby amended to read as follows:

34 35

232.320 1. The Director:

36 (a) Shall appoint, with the consent of the Governor,
37 administrators of the divisions of the Department, who are
38 respectively designated as follows:

39 (1) The Administrator of the Aging and Disability Services
 40 Division;

41 (2) The Administrator of the Division of Welfare and 42 Supportive Services;

43 (3) The Administrator of the Division of Child and Family
44 Services;





1 (4) The Administrator of the Division of Health Care 2 Financing and Policy; and

3 (5) The Administrator of the Division of Public and 4 Behavioral Health.

5 (b) Shall administer, through the divisions of the Department, 6 the provisions of chapters 63, 424, 425, 427A, 432A to 442, 7 inclusive, 446 to 450, inclusive, 458A and 656A of NRS, NRS 8 127.220 to 127.310, inclusive, 422.001 to 422.410, inclusive, and 9 section 31 of this act, 422.580, 432.010 to 432.133, inclusive, 432B.621 to 432B.626, inclusive, 444.002 to 444.430, inclusive, 10 and 445A.010 to 445A.055, inclusive, and all other provisions of 11 12 law relating to the functions of the divisions of the Department, but 13 is not responsible for the clinical activities of the Division of Public 14 and Behavioral Health or the professional line activities of the other 15 divisions.

16 (c) Shall administer any state program for persons with 17 developmental disabilities established pursuant to the 18 Developmental Disabilities Assistance and Bill of Rights Act of 19 2000, 42 U.S.C. §§ 15001 et seq.

(d) Shall, after considering advice from agencies of local
governments and nonprofit organizations which provide social
services, adopt a master plan for the provision of human services in
this State. The Director shall revise the plan biennially and deliver a
copy of the plan to the Governor and the Legislature at the
beginning of each regular session. The plan must:

26 (1) Identify and assess the plans and programs of the 27 Department for the provision of human services, and any 28 duplication of those services by federal, state and local agencies;

29

(2) Set forth priorities for the provision of those services;

30 (3) Provide for communication and the coordination of those
31 services among nonprofit organizations, agencies of local
32 government, the State and the Federal Government;

33 (4) Identify the sources of funding for services provided by34 the Department and the allocation of that funding;

(5) Set forth sufficient information to assist the Department
 in providing those services and in the planning and budgeting for the
 future provision of those services; and

38 (6) Contain any other information necessary for the effectively 39 to communicate with the Department Federal 40 Government concerning demographic trends, formulas for the 41 distribution of federal money and any need for the modification of 42 programs administered by the Department.

43 (e) May, by regulation, require nonprofit organizations and state
44 and local governmental agencies to provide information regarding
45 the programs of those organizations and agencies, excluding



2 Director deems necessary for the performance of the duties imposed
3 upon him or her pursuant to this section.
4 (f) Has such other powers and duties as are provided by law.
5 2. Notwithstanding any other provision of law, the Director, or
6 the Director's designee, is responsible for appointing and removing
7 subordinate officers and employees of the Department, other than
8 the State Public Defender of the Office of State Public Defender

9 who is appointed pursuant to NRS 180.010.

10 Sec. 26. NRS 233B.039 is hereby amended to read as follows:

11 233B.039 1. The following agencies are entirely exempted 12 from the requirements of this chapter:

13 (a) The Governor.

1

14 (b) Except as otherwise provided in NRS 209.221, the 15 Department of Corrections.

16 (c) The Nevada System of Higher Education.

- 17 (d) The Office of the Military.
- 18 (e) The Nevada Gaming Control Board.

(f) Except as otherwise provided in NRS 368A.140 and 463.765,the Nevada Gaming Commission.

(g) Except as otherwise provided in NRS 425.620, the Division
 of Welfare and Supportive Services of the Department of Health and
 Human Services.

(h) Except as otherwise provided in NRS 422.390, the Division
of Health Care Financing and Policy of the Department of Health
and Human Services.

(i) The State Board of Examiners acting pursuant to chapter 217of NRS.

(j) Except as otherwise provided in NRS 533.365, the Office ofthe State Engineer.

(k) The Division of Industrial Relations of the Department of
 Business and Industry acting to enforce the provisions of
 NRS 618.375.

(1) The Administrator of the Division of Industrial Relations of
the Department of Business and Industry in establishing and
adjusting the schedule of fees and charges for accident benefits
pursuant to subsection 2 of NRS 616C.260.

(m) The Board to Review Claims in adopting resolutions to
 carry out its duties pursuant to NRS 445C.310.

40 (n) The Silver State Health Insurance Exchange.

2. Except as otherwise provided in subsection 5 and NRS
391.323, the Department of Education, the Board of the Public
Employees' Benefits Program and the Commission on Professional

44 Standards in Education are subject to the provisions of this chapter





detailed information relating to their budgets and payrolls, which the

1 for the purpose of adopting regulations but not with respect to any 2 contested case. 3

The special provisions of: 3.

(a) Chapter 612 of NRS for the distribution of regulations by 4 5 and the judicial review of decisions of the Employment Security 6 Division of the Department of Employment, Training and 7 Rehabilitation;

8 (b) Chapters 616A to 617, inclusive, of NRS for the determination of contested claims; 9

(c) Chapter 91 of NRS for the judicial review of decisions of the 10 Administrator of the Securities Division of the Office of the 11 12 Secretary of State; and

13 (d) NRS 90.800 for the use of summary orders in contested 14 cases.

15  $\rightarrow$  prevail over the general provisions of this chapter.

16 4. The provisions of NRS 233B.122, 233B.124, 233B.125 and 17 233B.126 do not apply to the Department of Health and Human Services in the adjudication of contested cases involving the 18 19 issuance of letters of approval for health facilities and agencies.

20

The provisions of this chapter do not apply to: 5.

21 (a) Any order for immediate action, including, but not limited 22 to, quarantine and the treatment or cleansing of infected or infested 23 animals, objects or premises, made under the authority of the State 24 Board of Agriculture, the State Board of Health, or any other agency 25 of this State in the discharge of a responsibility for the preservation 26 of human or animal health or for insect or pest control;

27 (b) An extraordinary regulation of the State Board of Pharmacy 28 adopted pursuant to NRS 453.2184;

29 (c) A regulation adopted by the State Board of Education 30 pursuant to NRS 388.255 or 394.1694;

(d) The judicial review of decisions of the Public Utilities 31 32 Commission of Nevada: or

33 (e) The adoption, amendment or repeal of policies by the Rehabilitation Division of the Department of Employment, Training 34 35 and Rehabilitation pursuant to NRS 426.561 or 615.178.

(f) An upper payment limit prescribed by the Prescription 36 37 Drug Affordability Board pursuant to section 21 of this act.

38 6. The State Board of Parole Commissioners is subject to the 39 provisions of this chapter for the purpose of adopting regulations but 40 not with respect to any contested case.

41 **Sec. 27.** NRS 239.010 is hereby amended to read as follows:

42 239.010 1. Except as otherwise provided in this section and NRS 1.4683, 1.4687, 1A.110, 3.2203, 41.071, 49.095, 49.293, 43 62D.420, 62D.440, 62E.516, 62E.620, 62H.025, 62H.030, 62H.170, 44 45 62H.220, 62H.320, 75A.100, 75A.150, 76.160, 78.152, 80.113,



81.850, 82.183, 86.246, 86.54615, 87.515, 87.5413, 87A.200, 1 2 87A.580, 87A.640, 88.3355, 88.5927, 88.6067, 88A.345, 88A.7345, 89.045, 89.251, 90.730, 91.160, 116.757, 116A.270, 116B.880, 3 118B.026, 119.260, 119.265, 119.267, 119.280, 4 119A.280. 119A.653, 119B.370, 119B.382, 120A.690, 125.130, 125B.140, 5 126.141, 126.161, 126.163, 126.730, 127.007, 127.057, 127.130, 6 7 127.140, 127.2817, 128.090, 130.312, 130.712, 136.050, 159.044, 8 159A.044, 172.075, 172.245, 176.01249, 176.015, 176.0625, 176.09129, 176.156, 176A.630, 178.39801, 178.4715, 178.5691, 9 179.495, 179A.070, 179A.165, 179D.160, 200.3771, 200.3772, 10 200.5095, 200.604, 202.3662, 205.4651, 209.392, 209.3925, 11 209.419, 209.521, 211A.140, 213.010, 213.040, 213.095, 213.131, 12 217.110, 217.464, 217.475, 218A.350, 13 217.105, 218E.625, 218F.150, 218G.130, 218G.240, 218G.350, 228.270, 228.450, 14 228.495, 228.570, 231.069, 231.1473, 233.190, 237.300, 239.0105, 15 239.0113, 239B.030, 239B.040, 239B.050, 239C.140, 239C.210, 16 239C.230, 239C.250, 239C.270, 240.007, 241.020, 17 241.030. 241.039, 242.105, 244.264, 244.335, 247.540, 247.550, 247.560, 18 250.087, 250.130, 250.140, 250.150, 268.095, 268.490, 268.910, 19 271A.105, 281.195, 281.805, 281A.350, 281A.680, 281A.685, 20 281A.750, 281A.755, 281A.780, 284.4068, 286.110, 287.0438, 21 22 289.025, 289.080, 289.387, 289.830, 293.4855, 293.5002, 293.503, 293.504, 293.558, 293.906, 293.908, 293.910, 293B.135, 293D.510, 23 331.110, 332.061, 332.351, 333.333, 333.335, 338.070, 338.1379, 24 338.1593, 338.1725, 338.1727, 348.420, 349.597, 349.775, 353.205, 25 353A.049, 353A.085, 353A.100, 353C.240, 360.240, 360.247, 26 360.255, 360.755, 361.044, 361.610, 365.138, 366.160, 368A.180, 27 28 370.257, 370.327, 372A.080, 378.290, 378.300, 379.008, 379.1495, 29 385A.830, 385B.100, 387.626, 387.631, 388.1455, 388.259, 30 388.501, 388.503, 388.513, 388.750, 388A.247, 388A.249, 391.035, 391.120, 391.925, 392.029, 392.147, 392.264, 392.271, 392.315, 31 392.317, 392.325, 392.327, 392.335, 392.850, 394.167, 394.1698, 32 394.447, 394.460, 394.465, 396.3295, 396.405, 396.525, 396.535, 33 396.9685, 398A.115, 408.3885, 408.3886, 408.3888, 408.5484, 34 412.153, 416.070, 422.2749, 422.305, 422A.342, 422A.350, 35 425.400, 427A.1236, 427A.872, 432.028, 432.205, 432B.175, 36 432B.280, 432B.290, 432B.407, 432B.430, 432B.560, 432B.5902, 37 433A.360, 437.145, 439.840, 439B.420, 38 433.534, 440.170. 441A.220, 441A.230, 442.330, 442.395, 39 441A.195, 442.735. 445B.570, 449.209, 449.245, 449A.112, 40 445A.665, 450.140. 453.164, 453.720, 453A.610, 453A.700, 458.055, 458.280, 459.050, 41 42 459.3866. 459.555, 459.7056, 459.846, 463.120, 463.15993, 43 463.240, 463.3403, 463.3407, 463.790, 467.1005, 480.365, 480.940, 481.063, 481.091, 481.093, 482.170, 482.5536, 483.340, 483.363, 44 483.575, 483.659, 483.800, 484E.070, 485.316, 501.344, 503.452, 45



522.040, 534A.031, 561.285, 571.160, 584.655, 587.877, 598.0964, 1 2 598.098. 598A.110. 599B.090. 603.070. 603A.210. 604A.710. 612.265, 616B.012, 616B.015, 616B.315, 616B.350, 618.341, 3 618.425, 622.310, 623.131, 623A.137, 624.110, 624.265, 624.327, 4 5 625.425, 625A.185, 628.418, 628B.230, 628B.760, 629.047. 6 629.069. 630.133, 630.30665, 630.336, 630A.555, 631.368. 7 632.121, 632.125, 632.405, 633.283, 633.301, 633.524, 634.055, 8 634.214, 634A.185, 635.158, 636.107, 637.085, 637B.288, 638.087, 638.089, 639.2485, 639.570, 640.075, 640A.220, 9 640B.730. 640C.400, 640C.600, 640C.620, 640C.745, 640C.760, 640D.190, 10 640E.340, 641.090, 641.325, 641A.191, 641A.289, 641B.170, 11 641B.460, 641C.760, 641C.800, 642.524, 643.189, 644A.870, 12 13 645.180, 645.625, 645A.050, 645A.082, 645B.060, 645B.092, 645C.220, 645C.225, 645D.130, 645D.135, 645E.300, 645E.375, 14 645G.510, 645H.320, 645H.330, 647.0945, 647.0947, 648.033, 15 648.197, 649.065, 649.067, 652.228, 654.110, 656.105, 661.115, 16 17 665.130, 665.133, 669.275, 669.285, 669A.310, 671.170, 673.450, 673.480, 675.380, 676A.340, 676A.370, 677.243, 18 679B.122. 679B.152, 679B.159, 679B.190, 679B.285, 679B.690, 680A.270, 19 20 681A.440, 681B.260, 681B.410, 681B.540, 683A.0873, 685A.077, 21 686A.289, 686B.170, 686C.306, 687A.110, 687A.115, 687C.010, 22 688C.230, 688C.480, 688C.490, 689A.696, 692A.117, 692C.190, 692C.354. 23 692C.3507, 692C.3536, 692C.3538, 692C.420. 24 693A.480, 693A.615, 696B.550, 696C.120, 703.196, 704B.320, 704B.325, 706.1725, 706A.230, 710.159, 711.600, and section 20 25 26 of this act, sections 35, 38 and 41 of chapter 478, Statutes of Nevada 2011 and section 2 of chapter 391, Statutes of Nevada 2013 27 28 and unless otherwise declared by law to be confidential, all public 29 books and public records of a governmental entity must be open at all times during office hours to inspection by any person, and may 30 be fully copied or an abstract or memorandum may be prepared 31 32 from those public books and public records. Any such copies, 33 abstracts or memoranda may be used to supply the general public with copies, abstracts or memoranda of the records or may be used 34 35 in any other way to the advantage of the governmental entity or of 36 the general public. This section does not supersede or in any manner 37 affect the federal laws governing copyrights or enlarge, diminish or 38 affect in any other manner the rights of a person in any written book 39 or record which is copyrighted pursuant to federal law.

40 2. A governmental entity may not reject a book or record 41 which is copyrighted solely because it is copyrighted.

42 3. A governmental entity that has legal custody or control of a 43 public book or record shall not deny a request made pursuant to 44 subsection 1 to inspect or copy or receive a copy of a public book or 45 record on the basis that the requested public book or record contains





1 information that is confidential if the governmental entity can 2 redact, delete, conceal or separate the confidential information from

3 the information included in the public book or record that is not 4 otherwise confidential.

5 4. A person may request a copy of a public record in any 6 medium in which the public record is readily available. An officer, 7 employee or agent of a governmental entity who has legal custody 8 or control of a public record:

9 (a) Shall not refuse to provide a copy of that public record in a 10 readily available medium because the officer, employee or agent has 11 already prepared or would prefer to provide the copy in a different 12 medium.

(b) Except as otherwise provided in NRS 239.030, shall, upon
request, prepare the copy of the public record and shall not require
the person who has requested the copy to prepare the copy himself
or herself.

Sec. 28. NRS 241.016 is hereby amended to read as follows:

18 241.016 1. The meetings of a public body that are quasi-19 judicial in nature are subject to the provisions of this chapter.

20 2. The following are exempt from the requirements of this 21 chapter:

22 (a) The Legislature of the State of Nevada.

(b) Judicial proceedings, including, without limitation,
proceedings before the Commission on Judicial Selection and,
except as otherwise provided in NRS 1.4687, the Commission on
Judicial Discipline.

(c) Meetings of the State Board of Parole Commissioners when
 acting to grant, deny, continue or revoke the parole of a prisoner or
 to establish or modify the terms of the parole of a prisoner.

30 3. Any provision of law, including, without limitation, NRS 91.270, 219A.210, 228.495, 239C.140, 281A.350, 281A.690, 31 281A.735, 281A.760, 284.3629, 286.150, 287.0415, 287.04345, 32 287.338, 288.220, 289.387, 295.121, 360.247, 388.261, 388A.495, 33 388C.150, 388G.710, 388G.730, 392.147, 392.467, 394.1699, 34 396.3295, 433.534, 435.610, 463.110, 622.320, 622.340, 630.311, 35 36 630.336, 631.3635, 639.050, 642.518, 642.557, 686B.170. 37 696B.550, 703.196 and 706.1725 **[]** and section 13 of this act, 38 which:

39 (a) Provides that any meeting, hearing or other proceeding is not40 subject to the provisions of this chapter; or

41 (b) Otherwise authorizes or requires a closed meeting, hearing 42 or proceeding,

43  $\rightarrow$  prevails over the general provisions of this chapter.

44 4. The exceptions provided to this chapter, and electronic 45 communication, must not be used to circumvent the spirit or letter of





this chapter to deliberate or act, outside of an open and public
 meeting, upon a matter over which the public body has supervision,
 control, jurisdiction or advisory powers.

4

**Sec. 29.** NRS 287.010 is hereby amended to read as follows:

5 287.010 1. The governing body of any county, school 6 district, municipal corporation, political subdivision, public 7 corporation or other local governmental agency of the State of 8 Nevada may:

9 (a) Adopt and carry into effect a system of group life, accident 10 or health insurance, or any combination thereof, for the benefit of its 11 officers and employees, and the dependents of officers and 12 employees who elect to accept the insurance and who, where 13 necessary, have authorized the governing body to make deductions 14 from their compensation for the payment of premiums on the 15 insurance.

16 (b) Purchase group policies of life, accident or health insurance, 17 or any combination thereof, for the benefit of such officers and 18 employees, and the dependents of such officers and employees, as 19 have authorized the purchase, from insurance companies authorized 20 to transact the business of such insurance in the State of Nevada, 21 and, where necessary, deduct from the compensation of officers and 22 employees the premiums upon insurance and pay the deductions 23 upon the premiums.

24 (c) Provide group life, accident or health coverage through a 25 self-insurance reserve fund and, where necessary, deduct 26 contributions to the maintenance of the fund from the compensation 27 of officers and employees and pay the deductions into the fund. The 28 money accumulated for this purpose through deductions from the 29 compensation of officers and employees and contributions of the governing body must be maintained as an internal service fund as 30 31 defined by NRS 354.543. The money must be deposited in a state or 32 national bank or credit union authorized to transact business in the 33 State of Nevada. Any independent administrator of a fund created under this section is subject to the licensing requirements of chapter 34 35 683A of NRS, and must be a resident of this State. Any contract 36 with an independent administrator must be approved by the 37 Commissioner of Insurance as to the reasonableness 38 administrative charges in relation to contributions collected and benefits provided. The provisions of NRS 687B.408, 689B.030 to 39 40 689B.050, inclusive, and 689B.287 and section 33 of this act apply 41 to coverage provided pursuant to this paragraph, except that the 42 provisions of NRS 689B.0378 and 689B.03785 only apply to 43 coverage for active officers and employees of the governing body, 44 or the dependents of such officers and employees.





1 (d) Defray part or all of the cost of maintenance of a self-2 insurance fund or of the premiums upon insurance. The money for 3 contributions must be budgeted for in accordance with the laws 4 governing the county, school district, municipal corporation, 5 political subdivision, public corporation or other local governmental 6 agency of the State of Nevada.

7 2. If a school district offers group insurance to its officers and 8 employees pursuant to this section, members of the board of trustees 9 of the school district must not be excluded from participating in the 9 group insurance. If the amount of the deductions from compensation 11 required to pay for the group insurance exceeds the compensation to 12 which a trustee is entitled, the difference must be paid by the trustee.

13 3. In any county in which a legal services organization exists, 14 the governing body of the county, or of any school district, 15 municipal corporation, political subdivision, public corporation or 16 other local governmental agency of the State of Nevada in the 17 county, may enter into a contract with the legal services 18 organization pursuant to which the officers and employees of the 19 legal services organization, and the dependents of those officers and employees, are eligible for any life, accident or health insurance 20 21 provided pursuant to this section to the officers and employees, and 22 the dependents of the officers and employees, of the county, school 23 district, municipal corporation, political subdivision, public 24 corporation or other local governmental agency.

4. If a contract is entered into pursuant to subsection 3, the officers and employees of the legal services organization:

(a) Shall be deemed, solely for the purposes of this section, to be
officers and employees of the county, school district, municipal
corporation, political subdivision, public corporation or other local
governmental agency with which the legal services organization has
contracted; and

(b) Must be required by the contract to pay the premiums or
contributions for all insurance which they elect to accept or of which
they authorize the purchase.

5. A contract that is entered into pursuant to subsection 3:

(a) Must be submitted to the Commissioner of Insurance for
approval not less than 30 days before the date on which the contract
is to become effective.

39 (b) Does not become effective unless approved by the 40 Commissioner.

41 (c) Shall be deemed to be approved if not disapproved by the 42 Commissioner within 30 days after its submission.

6. As used in this section, "legal services organization" means
an organization that operates a program for legal aid and receives
money pursuant to NRS 19.031.





1 Sec. 30. NRS 287.04335 is hereby amended to read as 2 follows:

287.04335 If the Board provides health insurance through a 3 plan of self-insurance, it shall comply with the provisions of NRS 4 5 687B.409, 689B.255, 695G.150, 695G.160, 695G.162, 695G.164, 6 695G.1645, 695G.1665, 695G.167, 695G.170 to 695G.173, 7 inclusive, 695G.177, 695G.200 to 695G.230, inclusive, 695G.241 to 8 695G.310, inclusive, and 695G.405 **H** and section 33 of this act, in 9 the same manner as an insurer that is licensed pursuant to title 57 of 10 NRS is required to comply with those provisions.

11 Sec. 31. Chapter 422 of NRS is hereby amended by adding 12 thereto a new section to read as follows:

13 1. Except as otherwise provided in subsection 2, the Department shall directly manage, direct and coordinate all 14 15 payments and rebates for prescription drugs and all other services 16 and payments relating to the provision of prescription drugs under 17 the State Plan for Medicaid and the Children's Health Insurance 18 **Program**.

19 The Department may enter into a contract with a 2. 20 pharmacy benefit manager for the provision of any services described in subsection 1. Such a contract must require the 21 22 pharmacy benefit manager to disclose to the Department any information relating to the services covered by the contract, 23 24 including, without limitation, information concerning dispensing 25 fees, measures for the control of costs, rebates collected and paid 26 and any fees and charges imposed by the pharmacy benefit 27 manager pursuant to the contract.

3. As used in this section, "pharmacy benefit manager" has 28 the meaning ascribed to it in NRS 683A.174. 29

30

**Sec. 32.** NRS 683A.179 is hereby amended to read as follows: 31 683A.179 1. A pharmacy benefit manager shall not:

32 (a) Prohibit a pharmacist or pharmacy from providing 33 information to a covered person concerning the amount of any copayment or coinsurance for a prescription drug or informing a 34 covered person concerning the clinical efficacy of a less expensive 35 36 alternative drug:

37 (b) Penalize a pharmacist or pharmacy for providing the information described in paragraph (a) or selling a less expensive 38 39 alternative drug to a covered person;

(c) Prohibit a pharmacy from offering or providing delivery 40 services directly to a covered person as an ancillary service of the 41 42 pharmacy; [or]

43 (d) If the pharmacy benefit manager manages a pharmacy 44 benefits plan that provides coverage through a network plan, charge 45 a copayment or coinsurance for a prescription drug in an amount





1 that is greater than the total amount paid to a pharmacy that is in the 2 network of providers under contract with the third party [-]; or

3 (e) Pay or arrange for the payment of an amount for a 4 prescription drug that exceeds any upper payment limit prescribed 5 for that drug pursuant to section 21 of this act. For the purposes 6 of this paragraph, the amount paid for a prescription drug means 7 the price paid for the drug, less any rebates received by the payor.

8 2. As used in this section, "network plan" means a health 9 benefit plan offered by a health carrier under which the financing 10 and delivery of medical care is provided, in whole or in part, 11 through a defined set of providers under contract with the carrier. 12 The term does not include an arrangement for the financing of 13 premiums.

14 **Sec. 33.** Chapter 687B of NRS is hereby amended by adding 15 thereto a new section to read as follows:

16 1. A health carrier shall not pay an amount for a prescription 17 drug that exceeds any upper payment limit prescribed for that 18 drug pursuant to section 21 of this act.

19 **2.** For the purposes of this section, the amount paid by a 20 health carrier for a prescription drug means the price paid for the 21 drug, less any rebates received by the health carrier.

22 3. As used in this section, "health carrier" has the meaning 23 ascribed to it in NRS 695G.024.

24 **Sec. 34.** NRS 695C.1703 is hereby amended to read as 25 follows:

695C.1703 1. A health maintenance organization or insurer that offers or issues evidence of coverage which provides coverage for prescription drugs shall include with any evidence of that coverage provided to an enrollee, notice of whether a formulary is used and, if so, of the opportunity to secure information regarding the formulary from the organization or insurer pursuant to subsection 2. The notice required by this subsection must:

(a) Be in a language that is easily understood and in a format
 that is easy to understand;

- (b) Include an explanation of what a formulary is; and
- 35 36
- (c) If a formulary is used, include: (1) An explanation of:
- 37 38
- (1) An explanation of:

(I) How often the contents of the formulary are reviewed;and

40 (II) The procedure and criteria for determining which 41 prescription drugs are included in and excluded from the formulary; 42 and

43 (2) The telephone number of the organization or insurer for
44 making a request for information regarding the formulary pursuant
45 to subsection 2.





1 2. If a health maintenance organization or insurer offers or 2 issues evidence of coverage which provides coverage for 3 prescription drugs and a formulary is used, the organization or 4 insurer shall:

5 (a) Provide to any enrollee or participating provider of health 6 care upon request:

7 (1) Information regarding whether a specific drug is included 8 in the formulary.

9 (2) Access to the most current list of prescription drugs in the 10 formulary, organized by major therapeutic category, with an 11 indication of whether any listed drugs are preferred over other listed 12 drugs. If more than one formulary is maintained, the organization or 13 insurer shall notify the requester that a choice of formulary lists is 14 available.

(b) Notify each person who requests information regarding the
formulary, that the inclusion of a drug in the formulary does not
guarantee that a provider of health care will prescribe that drug for a
particular medical condition.

A health maintenance organization that provides coverage 19 *3*. 20 for prescription drugs through managed care to recipients of 21 Medicaid under the State Plan for Medicaid or the Children's 22 Health Insurance Program pursuant to a contract with the 23 Division of Health Care Financing and Policy of the Department of Health and Human Services shall use as the formulary for 24 25 prescription drug coverage the list of preferred prescription drugs 26 prescribed by the Department pursuant to NRS 422.4025 to be 27 used for the Medicaid program.

28 Sec. 35. Section 21 of this act is hereby amended to read as 29 follows:

30 Sec. 21. 1. If, after conducting a review pursuant to section 19 of this act, the Board determines that the price of a 31 32 prescription drug is creating significant challenges for insurers and patients in this State, the Board shall prescribe a 33 **[recommended]** *mandatory* upper payment limit 34 for purchases of the prescription drug in this State. When 35 establishing a [recommended] mandatory upper payment 36 37 limit for a prescription drug, the Board shall consider, to the 38 extent that such information is available and relevant:

39

(a) The cost of administering the prescription drug;

40 (b) The cost of delivering the prescription drug to 41 consumers;

42 (c) Any other relevant administrative costs related to the 43 prescription drug; and

44

(d) The information described in section 19 of this act.





2. The Board may revise or rescind a [recommended] *mandatory* upper payment limit imposed pursuant to this section if, after conducting a review pursuant to section 19 of this act, it determines that conditions warrant the revision or rescinding of the upper payment limit, as applicable.

3. The Board shall collaborate with the Council, manufacturers, health carriers, consumers of prescription drugs and other interested persons to:

(a) Establish and refine a methodology to for prescribing upper payment limits pursuant to this section; and

11 (b) Improve the quality and quantity of information 12 received by the Board pursuant to section 20 of this act.

13 Sec. 36. Section 31 of this act is hereby amended to read as 14 follows:

Sec. 31. 1. Except as otherwise provided in subsection 2, the Department shall directly manage, direct and coordinate all payments and rebates for prescription drugs and all other services and payments relating to the provision of prescription drugs under the State Plan for Medicaid and the Children's Health Insurance Program.

21 2. The Department may enter into a contract with a 22 pharmacy benefit manager for the provision of any services 23 described in subsection 1. Such a contract must require the 24 pharmacy benefit manager to disclose to the Department any 25 information relating to the services covered by the contract, 26 including. without limitation. information concerning 27 dispensing fees, measures for the control of costs, rebates 28 collected and paid and any fees and charges imposed by the 29 pharmacy benefit manager pursuant to the contract.

The Department shall not pay an amount for the 30 3. 31 prescription drug distributed pursuant to Medicaid or the 32 Children's Health Insurance Program that exceeds any 33 upper payment limit prescribed for that drug pursuant to 34 section 21 of this act. For the purposes of this subsection, 35 the amount paid for a prescription drug means the price 36 paid for the drug, less any rebates received by the 37 Department. 38

**4.** As used in this section, "pharmacy benefit manager" has the meaning ascribed to it in NRS 683A.174.

40 Sec. 37. 1. As soon as practicable after July 1, 2019:

(a) The Governor and the Majority Leader of the Senate shallappoint to the Prescription Drug Affordability Board:

43 (1) The regular members described in paragraphs (a) and (b),
44 respectively, of subsection 1 of section 12 of this act to terms of 2
45 years; and



1

2

3

4

5

6

7

8

9 10

15

16

17

18

19

20



1 (2) The alternate members described in paragraphs (a) and 2 (b), respectively, of subsection 2 of section 12 of this act to terms of 3 4 years.

4 (b) The Speaker of the Assembly, the Attorney General and the 5 Majority Leader of the Senate and Speaker of the Assembly shall 6 appoint to the Prescription Drug Affordability Board the regular 7 members described in paragraphs (c), (d) and (e), respectively, of 8 subsection 1 of section 12 of this act to terms of 4 years.

9 (c) The Speaker of the Assembly shall appoint to the 10 Prescription Drug Affordability Board the alternate member 11 described in paragraph (c) of subsection 2 of section 12 of this act to 12 a term of 2 years.

2. As used in this section, "Prescription Drug Affordability
Board" means the Prescription Drug Affordability Board established
by section 12 of this act.

16 Sec. 38. 1. As soon as practicable after July 1, 2019:

17 (a) The Speaker of the Assembly shall appoint to the 18 Prescription Drug Affordability Stakeholder Council:

19 (1) The members described in paragraphs (a), (b) and (c) of 20 subsection 2 of section 15 of this act to terms of 1 year;

(2) The member described in paragraph (d) of subsection 2
of section 15 of this act and one member described in paragraph (e)
of subsection 2 of section 15 of this act to terms of 2 years; and

(3) One member described in paragraph (e) of subsection 2
of section 15 of this act and the member described in paragraph (f)
of subsection 2 of section 15 of this act to terms of 3 years.

(b) The Majority Leader of the Senate shall appoint to thePrescription Drug Affordability Stakeholder Council:

29 (1) The members described in paragraphs (a) and (g) of 30 subsection 3 of section 15 of this act to terms of 1 year;

31 (2) The members described in paragraphs (b), (c) and (d) of 32 subsection 3 of section 15 of this act to terms of 2 years; and

(3) The members described in paragraphs (e) and (f) ofsubsection 3 of section 15 of this act to terms of 3 years.

35 (c) The Governor shall appoint to the Prescription Drug 36 Affordability Stakeholder Council:

37 (1) The members described in paragraphs (a) and (b) of 38 subsection 3 of section 15 of this act to terms of 1 year;

39 (2) The members described in paragraphs (c) and (g) of 40 subsection 3 of section 15 of this act to terms of 2 years; and

41 (3) The members described in paragraphs (d), (e) and (f) of 42 subsection 3 of section 15 of this act to terms of 3 years.

2. As used in this section, "Prescription Drug Affordability
Stakeholder Council" means the Prescription Drug Affordability
Stakeholder Council established by section 15 of this act.





1 Sec. 39. 1. For each prescription drug for which the 2 Prescription Drug Affordability Board has adopted a recommended 3 upper payment limit pursuant to section 21 of this act, as that section existed on December 31, 2023, the Board shall, as soon as 4 5 practicable after January 1, 2024:

6 (a) Conduct a review of the price of the prescription drug 7 pursuant to section 19 of this act to consider any new information 8 concerning the price of the prescription drug; and

9 (b) If the Board determines that the price of the prescription drug is creating significant challenges for health carriers and 10 patients in this State on the date of the review, prescribe a 11 12 mandatory upper payment limit for the prescription drug in 13 accordance with the provisions of section 21 of this act, as amended 14 by section 35 of this act.

15

2. As used in this section:

(a) "Health carrier" has the meaning ascribed to it in section 7 of 16 17 this act.

18 (b) "Prescription Drug Affordability Board" means the Prescription Drug Affordability Board established by section 12 of 19 20 this act.

21 (c) "Upper payment limit" has the meaning ascribed to it in 22 section 10 of this act.

Sec. 40. The amendatory provisions of sections 29 to 35, 23 24 inclusive, of this act apply to any contract or other agreement 25 entered into before, on or after January 1, 2024.

26 Sec. 41. The provisions of subsection 1 of NRS 218D.380 do not apply to any provision of this act which adds or revises a 27 28 requirement to submit a report to the Legislature.

29 Sec. 42. 1. This section and sections 1 to 28, inclusive, 31, 30 34, 37, 38, 40 and 41 of this act become effective on July 1, 2019.

2. Sections 29, 30, 32, 33, 35, 36 and 39 of this act become 31 32 effective on January 1, 2024.

(30)



